101 related articles for article (PubMed ID: 2569929)
1. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice.
Avery TL; Rehg JE; Lumm WC; Harwood FC; Santana VM; Blakley RL
Cancer Res; 1989 Sep; 49(18):4972-8. PubMed ID: 2569929
[TBL] [Abstract][Full Text] [Related]
2. Effects of cytotoxicity of 2-chloro-2'-deoxyadenosine and 2-bromo-2'-deoxyadenosine on cell growth, clonogenicity, DNA synthesis, and cell cycle kinetics.
Huang MC; Ashmun RA; Avery TL; Kuehl M; Blakley RL
Cancer Res; 1986 May; 46(5):2362-8. PubMed ID: 2421877
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells.
Griffig J; Koob R; Blakley RL
Cancer Res; 1989 Dec; 49(24 Pt 1):6923-8. PubMed ID: 2573423
[TBL] [Abstract][Full Text] [Related]
4. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy.
Carrera CJ; Terai C; Lotz M; Curd JG; Piro LD; Beutler E; Carson DA
J Clin Invest; 1990 Nov; 86(5):1480-8. PubMed ID: 1700795
[TBL] [Abstract][Full Text] [Related]
5. 5-Hexyl-2'-deoxyuridine blocks the cytotoxic effects of 5-fluorodeoxyuridine or deoxyadenosine in leukemia L1210 cells in culture.
Cory JG; Halley MC; Jeney A; Lapis K
Cancer Res; 1990 Aug; 50(15):4552-6. PubMed ID: 2142444
[TBL] [Abstract][Full Text] [Related]
6. Nucleotide excision repair-deficient human cells in culture exhibit decreased survival after 2-chlorodeoxyadenosine treatment.
Lawrenzi J; Bunnell A; Hentosh P
Anticancer Res; 2003; 23(4):3141-5. PubMed ID: 12926046
[TBL] [Abstract][Full Text] [Related]
7. Analysis of 2-chloro-2'-deoxyadenosine incorporation into cellular DNA by quantitative polymerase chain reaction.
Yuh SH; Tibudan M; Hentosh P
Anal Biochem; 1998 Aug; 262(1):1-8. PubMed ID: 9735141
[TBL] [Abstract][Full Text] [Related]
8. Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: its therapeutic implication for MTAP (-) malignancies.
Yu J; Batova A; Shao L; Carrera CJ; Yu AL
Clin Cancer Res; 1997 Mar; 3(3):433-8. PubMed ID: 9815702
[TBL] [Abstract][Full Text] [Related]
9. Determinants of deoxyadenosine toxicity in hybrids between human T- and B- lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia.
Kurtzberg J; Hershfield MS
Cancer Res; 1985 Apr; 45(4):1579-86. PubMed ID: 3872167
[TBL] [Abstract][Full Text] [Related]
10. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210.
Góra-Tybor J; Robak T; Warzocha K; Grieb P
Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633
[TBL] [Abstract][Full Text] [Related]
11. Resistance to 2-chloro-2'-deoxyadenosine of the human B-cell leukemia cell line EHEB.
Cardoen S; Van Den Neste E; Smal C; Rosier JF; Delacauw A; Ferrant A; Van den Berghe G; Bontemps F
Clin Cancer Res; 2001 Nov; 7(11):3559-66. PubMed ID: 11705877
[TBL] [Abstract][Full Text] [Related]
12. The antileukemia drug 2-chloro-2'-deoxyadenosine: an intrinsic transcriptional antagonist.
Hartman WR; Hentosh P
Mol Pharmacol; 2004 Jan; 65(1):227-34. PubMed ID: 14722255
[TBL] [Abstract][Full Text] [Related]
13. Dipyridamole enhancement of toxicity to L1210 cells by deoxyadenosine and deoxycoformycin combinations in vitro.
Kang GJ; Kimball AP
Cancer Res; 1984 Feb; 44(2):461-6. PubMed ID: 6362851
[TBL] [Abstract][Full Text] [Related]
14. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
[TBL] [Abstract][Full Text] [Related]
16. Cytostatic effects of 2',3'-dideoxyribonucleosides on transformed human hemopoietic cell lines.
Blakley RL; Harwood FC; Huff KD
Mol Pharmacol; 1990 Feb; 37(2):328-32. PubMed ID: 2154678
[TBL] [Abstract][Full Text] [Related]
17. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
[TBL] [Abstract][Full Text] [Related]
18. 2,6-Diaminopurinedeoxyriboside as a prodrug of deoxyguanosine in L1210 cells.
Weckbecker G; Cory JG
Cancer Res; 1987 May; 47(9):2218-23. PubMed ID: 3552212
[TBL] [Abstract][Full Text] [Related]
19. Deoxyadenosine-resistant mouse leukemia L1210 cell lines with alterations in early response genes and p53.
Cory JG; He AW; Cory AH
Anticancer Res; 1996; 16(6B):3483-9. PubMed ID: 9042210
[TBL] [Abstract][Full Text] [Related]
20. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
